Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction
Özet
Objective: To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction. Materials and Methods: A total of 60 patients diagnosed with erectile dysfunction were retrospectively evaluated using the international index of erectile function questionnaire- 5 (IIEF-5), intravaginal ejaculatory latency time (IELT) and international prostate symptoms scores (IPSS). After the patients were treated with 5mg tadalafil once a day for three months, their erection, ejaculation and LUTS were assessed again. The fasting levels of blood glucose, total testosterone, low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol and total cholesterol were measured. The independentsamples t-test was used to compare the pre- and post-treatment scores of the patients. Results: The mean age of the 60 participants was 50.4±7.9 and the mean baseline serum total testosterone, total cholesterol, and fasting blood sugar were 444.6±178.6ng dL-1, 188.7±29.6mg/dL-1,104 (80-360) mg dL-1, respectively. The mean baseline scores were 2.2±1.4 min for IELT, 9.5±3.7 for IIEF-5 and 14.1±4.5 for IPSS. Following the three-month daily 5mg tadalafil treatment, the scores were found to be 3.4±1.9 min, 16.1±4.7, and 10.4±3.8 for IELT, IIEF and IPSS, respectively. When the baseline and post-treatment scores were compared, a statistically significant increase was observed in the IELTs and IIEF-5 values whereas there was a significant decrease in IPSS (p < 0.01). Conclusion: A daily dose of 5mg tadalafil can be safely used in the treatment of erectile dysfunction and LUTS, that prolongs the ejaculatory latency time.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Karabakan, Mehmet | |
| dc.contributor.author | Keskin, Ercument | |
| dc.contributor.author | Akdemir, Serkan | |
| dc.contributor.author | Bozkurt, Aliseydi | |
| dc.date.accessioned | 2026-10-18T20:29:27.051551446Z | |
| dc.date.available | 2026-10-18T20:29:27.051551446Z | |
| dc.date.issued | 2017 | |
| dc.description.abstract | Objective: To investigate the effect of a 5mg daily tadalafil treatment on the ejaculation time, erectile function and lower urinary tract symptoms (LUTS) in patients with erectile dysfunction. Materials and Methods: A total of 60 patients diagnosed with erectile dysfunction were retrospectively evaluated using the international index of erectile function questionnaire- 5 (IIEF-5), intravaginal ejaculatory latency time (IELT) and international prostate symptoms scores (IPSS). After the patients were treated with 5mg tadalafil once a day for three months, their erection, ejaculation and LUTS were assessed again. The fasting levels of blood glucose, total testosterone, low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol and total cholesterol were measured. The independentsamples t-test was used to compare the pre- and post-treatment scores of the patients. Results: The mean age of the 60 participants was 50.4±7.9 and the mean baseline serum total testosterone, total cholesterol, and fasting blood sugar were 444.6±178.6ng dL-1, 188.7±29.6mg/dL-1,104 (80-360) mg dL-1, respectively. The mean baseline scores were 2.2±1.4 min for IELT, 9.5±3.7 for IIEF-5 and 14.1±4.5 for IPSS. Following the three-month daily 5mg tadalafil treatment, the scores were found to be 3.4±1.9 min, 16.1±4.7, and 10.4±3.8 for IELT, IIEF and IPSS, respectively. When the baseline and post-treatment scores were compared, a statistically significant increase was observed in the IELTs and IIEF-5 values whereas there was a significant decrease in IPSS (p < 0.01). Conclusion: A daily dose of 5mg tadalafil can be safely used in the treatment of erectile dysfunction and LUTS, that prolongs the ejaculatory latency time. | |
| dc.identifier.doi | 10.1590/s1677-5538.ibju.2016.0376 | |
| dc.identifier.eissn | 1677-6119 | |
| dc.identifier.endpage | 324 | |
| dc.identifier.issn | 1677-5538 | |
| dc.identifier.issue | 2 | |
| dc.identifier.pmcid | PMC5433372 | |
| dc.identifier.pmid | 27819758 | |
| dc.identifier.scopus | 2-s2.0-85017472672 | |
| dc.identifier.startpage | 317 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/14648 | |
| dc.identifier.volume | 43 | |
| dc.identifier.wos | WOS:000396002900020 | |
| dc.language.iso | en | |
| dc.publisher | Brazilian Society of Urology | |
| dc.relation.ispartof | International Braz J Urol | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Ejaculation | |
| dc.subject | Erectile dysfunction | |
| dc.subject | Tadalafil | |
| dc.subject | Therapeutics | |
| dc.subject | Adult | |
| dc.subject | Aged | |
| dc.subject | Blood Glucose | |
| dc.subject | Cholesterol | |
| dc.subject | Drug Administration Schedule | |
| dc.subject | Humans | |
| dc.subject | Lower Urinary Tract Symptoms | |
| dc.subject | Male | |
| dc.subject | Middle Aged | |
| dc.subject | Penile Erection | |
| dc.subject | Phosphodiesterase 5 Inhibitors | |
| dc.subject | Premature Ejaculation | |
| dc.subject | Retrospective Studies | |
| dc.subject | Statistics, Nonparametric | |
| dc.subject | Surveys and Questionnaires | |
| dc.subject | Testosterone | |
| dc.subject | Time Factors | |
| dc.subject | Treatment Outcome | |
| dc.subject | glucose blood level | |
| dc.subject | phosphodiesterase V inhibitor | |
| dc.subject | analysis | |
| dc.subject | blood | |
| dc.subject | drug administration | |
| dc.subject | drug effects | |
| dc.subject | human | |
| dc.subject | nonparametric test | |
| dc.title | Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 18 | |
| rdl.citation.wos | 16 | |
| rdl.department | Department of Urology, Mengucek Gazi Research and Training Hospital, Erzincan University, Erzincan, Turkey. | |
| rdl.oa.status | gold | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
